Journal article
Obesity and survival among women with ovarian cancer: Results from the Ovarian Cancer Association Consortium
CM Nagle, SC Dixon, A Jensen, SK Kjaer, F Modugno, A DeFazio, S Fereday, J Hung, SE Johnatty, PA Fasching, MW Beckmann, D Lambrechts, I Vergote, E Van Nieuwenhuysen, S Lambrechts, HA Risch, MA Rossing, JA Doherty, KG Wicklund, J Chang-Claude Show all
British Journal of Cancer | SPRINGERNATURE | Published : 2015
DOI: 10.1038/bjc.2015.245
Abstract
Background: Observational studies have reported a modest association between obesity and risk of ovarian cancer; however, whether it is also associated with survival and whether this association varies for the different histologic subtypes are not clear. We undertook an international collaborative analysis to assess the association between body mass index (BMI), assessed shortly before diagnosis, progression-free survival (PFS), ovarian cancer-specific survival and overall survival (OS) among women with invasive ovarian cancer. Methods: We used original data from 21 studies, which included 12 390 women with ovarian carcinoma. We combined study-specific adjusted hazard ratios (HRs) using rand..
View full abstractGrants
Awarded by Mayo Foundation for Medical Education and Research
Funding Acknowledgements
We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of Ovarian Cancer Association Consortium through their donations to the Ovarian Cancer Research Fund. The Australian Ovarian Cancer Study Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green and PM Webb) and ACS Investigators (A Green, P Parsons, N Hayward, PM Webb and D Whiteman) thank all the clinical and scientific collaborators (see http://www.aocstudy.org/) and the women who participated in these studies for their contribution. We thank Gilian Peuteman, Thomas Van Brussel and Dominiek Smeets for technical assistance (for BEL). The cooperation of the 32 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. This study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in this study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. We assume full responsibility for analyses and interpretation of these data (for CON). The German Ovarian Cancer Study (GER) thank Ursula Eilber for competent technical assistance (for GER). Funding: The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund. This work was supported by the following: National Institutes of Health (R01-CA61107 (for MAL); R01-CA95023 and R01-CA126841 (for HOP); P01-CA17054 (for USC); NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563 and P30-CA072720 (for NJO); (R01-CA074850 and R01-CA080742 (for CON); R01-CA112523 and R01-CA087538 (for DOV); R01-CA058598, N01-CN-55424 and N01-PC-67001 (for HAW); R01-CA122443, P50-CA136393 and P30-CA15083 (for MAC and MAY); R01-CA076016 (for NCO); R01-CA054419 and P50-CA105009 (for NEC); U01-CA71966, R01-CA016056 and K07-CA143047 (for STA); R01-CA106414 (for TBO); R01CA058860, R01CA092044 and PSA042205 (for UCI); Department of Defense (DAMD17-02-1-0666 (for NCO); W81XWH-10-1-02802 (for NEC); DAMD17-02-1-0669 (for HOP); DAMD17-01-1-0729 (for AUS); DAMD17-98-1-8659 (for TBO); National Cancer Institute K07-CA80668 (for HOP); NIH/National Center for Research Resources/General Clinical Research Center grant MO1-RR000056 and P50-CA159981 (for HOP); National Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia; National Health and Medical Research Council of Australia (199600 and 400281) (for AUS); Danish Cancer Society, Copenhagen, Denmark (94 222 52) and the Mermaid I project (for MAL); FM supported by funding from K07-CA080668 (for HOP); California Cancer Research Program (00-01389V-20170, R03-CA113148, R03-CA115195, N01-CN25403 and 2II0200) (for USC); ELAN Funds of the University of Erlangen-Nuremberg (for BAV); Nationaal Kankerplan (for BEL); German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and data management by the German Cancer Research Center (for GER); Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, and by a grant from Takeda Science Foundation (for JPN); Mayo Foundation, Minnesota Ovarian Cancer Alliance, Fred C. and Katherine B.Andersen Foundation (for MAC and MAY); Cancer Institute of New Jersey (for NJO); Intramural Research Program of the National Cancer Institute (for POL); Cancer Prevention Institute of California (U01-CA69417) (for STA); American Cancer Society (CRTG-00-196-01-CCE), Celma Mastry Ovarian Cancer Foundation (for TBO); and Lon V Smith Foundation grant LVS-39420 (for UCI). PW is supported by a Fellowship from NHMRC and CN is supported by NHMRC Program grant 552429 (for AUS). AdF is supported by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney-West Translational Cancer Research Centre (for AUS).